GlaxoSmithKline S.A.E Statistics

Total Valuation

GlaxoSmithKline S.A.E has a market cap or net worth of EGP 3.52 billion. The enterprise value is 3.48 billion.

Market Cap	3.52B
Enterprise Value	3.48B

Important Dates

The next estimated earnings date is Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	Jul 18, 2024

Share Statistics

GlaxoSmithKline S.A.E has 83.51 million shares outstanding. The number of shares has increased by 0.19% in one year.

Shares Outstanding	83.51M
Shares Change (YoY)	+0.19%
Shares Change (QoQ)	-0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.43M

Valuation Ratios

The trailing PE ratio is 26.41.

PE Ratio	26.41
Forward PE	n/a
PS Ratio	1.36
PB Ratio	1.84
P/FCF Ratio	50.86
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.60, with an EV/FCF ratio of 50.24.

EV / Earnings	26.09
EV / Sales	1.34
EV / EBITDA	5.60
EV / EBIT	6.09
EV / FCF	50.24

Financial Position

The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.07.

Current Ratio	1.75
Quick Ratio	0.44
Debt / Equity	0.07
Debt / EBITDA	0.20
Debt / FCF	1.90
Interest Coverage	21.85

Financial Efficiency

Return on equity (ROE) is 6.95% and return on invested capital (ROIC) is 18.75%.

Return on Equity (ROE)	6.95%
Return on Assets (ROA)	10.94%
Return on Capital (ROIC)	18.75%
Revenue Per Employee	3.25M
Profits Per Employee	166,796
Employee Count	800
Asset Turnover	0.75
Inventory Turnover	1.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +49.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+49.77%
50-Day Moving Average	32.80
200-Day Moving Average	32.89
Relative Strength Index (RSI)	64.77
Average Volume (20 Days)	265,788

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GlaxoSmithKline S.A.E had revenue of EGP 2.60 billion and earned 133.44 million in profits. Earnings per share was 1.60.

Revenue	2.60B
Gross Profit	1.19B
Operating Income	606.37M
Pretax Income	240.07M
Net Income	133.44M
EBITDA	643.08M
EBIT	606.37M
Earnings Per Share (EPS)	1.60

Full Income Statement

Balance Sheet

The company has 175.30 million in cash and 131.98 million in debt, giving a net cash position of 43.33 million or 0.52 per share.

Cash & Cash Equivalents	175.30M
Total Debt	131.98M
Net Cash	43.33M
Net Cash Per Share	0.52
Equity (Book Value)	1.91B
Book Value Per Share	22.91
Working Capital	1.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 159.58 million and capital expenditures -90.28 million, giving a free cash flow of 69.30 million.

Operating Cash Flow	159.58M
Capital Expenditures	-90.28M
Free Cash Flow	69.30M
FCF Per Share	0.83

Full Cash Flow Statement

Margins

Gross margin is 45.66%, with operating and profit margins of 23.32% and 5.13%.

Gross Margin	45.66%
Operating Margin	23.32%
Pretax Margin	9.23%
Profit Margin	5.13%
EBITDA Margin	24.73%
EBIT Margin	23.32%
FCF Margin	2.67%

Dividends & Yields

This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.78%.

Dividend Per Share	0.75
Dividend Yield	1.78%
Dividend Growth (YoY)	-80.00%
Years of Dividend Growth	2
Payout Ratio	31.86%
Buyback Yield	-0.19%
Shareholder Yield	1.59%
Earnings Yield	3.79%
FCF Yield	1.97%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GlaxoSmithKline S.A.E has an Altman Z-Score of 2.95. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.95
Piotroski F-Score	n/a